Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Minrad International, an interventional pain management company, has notified RxElite Holdings, a wholly-owned subsidiary of RxElite Inc that it is transitioning its relationship with respect to RxElite Holdings's rights to be the exclusive distributor of certain Minrad International's anesthetic products in the US.
Subscribe to our email newsletter
Minrad has decided to move into a non-exclusive distributor arrangement with RxElite.
David DiGiacinto, president and COO of Minrad, said: “We had ongoing dialogue with the senior management of RxElite to assess and determine how to increase our joint penetration of anesthetic products in the US market.
“We believe this action will maximize the expertise of sales forces of both companies as well as the in-house support capabilities which RxElite has built to launch sevoflurane in the US human anesthetic market.”
Kirk Kamsler, Minrad’s senior vice president of commercial development, said: “We expect and will work towards ensuring that this ongoing change in selling strategy for our present and future anesthetics in the US market will be transparent to both the distribution customers and end users of this product.”